Concepedia

Min Yang

MY

Statistics

Publications

14

Citations

1.7K

H-Index

14

Active since

1995

Affiliations

Acetylon Pharmaceuticals (United States)(Current)

Harvard University

Massachusetts General Hospital

Dana-Farber Cancer Institute

Emory University

Min Yang is an author at Acetylon Pharmaceuticals (United States) specializing in medicine, oncology, and molecular oncology.

Publications per year

1995–2022

14

Publications

14

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood · 2012 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, Noopur Raje, Sundar Jagannath et al. · Clinical Cancer Research · 2017 · 251 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

Andrew J. Yee, William Bensinger, Jeffrey G. Supko et al. · The Lancet Oncology · 2016 · 199 citations

Medicine, Hematology, Pharmacotherapy +14

Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apcmin/+ mice

Li Lü, Xiaofei Li, Weilong Zhong et al. · EBioMedicine · 2019 · 150 citations · Full text

Medicine, Microbiology, Oncology +17

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

Pengyu Huang, Ingrid Almeciga-Pinto, Matthew Jarpe et al. · Oncotarget · 2016 · 128 citations · Full text

Medicine, Oncology, Pharmacology +16

1–5 of 14